HER-2/neu expression in germ cell tumours

S. Soule, K. Miller, L. Baldridge, K. Kirkpatrick, L. Cheng, J. L. Gilbert, L. R. Smith, V. C. Thurston, G. H. Vance, L. Einhorn

Research output: Contribution to journalArticle

26 Scopus citations


Aims: To determine the rate of HER-2/neu positivity of germ cell tumours by immunohistochemistry (IHC) and by fluorescence in situ hybridisation (FISH). Patients/Methods: Ninety six archival, paraffin wax embedded pathology specimens were chosen from four groups of germ cell tumours. IHC for HER-2/neu was performed with the HercepTest kit; FISH analysis was performed with the INFORM assay and confirmed with a centromere 17 probe. Results: Twenty two of 96 specimens overexpressed the HER-2/neu protein when measured by IHC. Only three specimens showed HER-2/neu gene amplification by FISH. There was no correlation between the results obtained by IHC and FISH. Conclusions: The lack of concordance between IHC and FISH makes it unlikely that overexpression of the HER-2/neu protein in germ cell tumours is of prognostic or therapeutic relevance. Because of the low rate of HER-2/neu gene amplification in germ cell tumours, a clinical trial of trastuzumab treatment in patients with germ cell tumours is not warranted.

Original languageEnglish (US)
Pages (from-to)656-658
Number of pages3
JournalJournal of clinical pathology
Issue number9
StatePublished - Sep 2002

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'HER-2/neu expression in germ cell tumours'. Together they form a unique fingerprint.

  • Cite this

    Soule, S., Miller, K., Baldridge, L., Kirkpatrick, K., Cheng, L., Gilbert, J. L., Smith, L. R., Thurston, V. C., Vance, G. H., & Einhorn, L. (2002). HER-2/neu expression in germ cell tumours. Journal of clinical pathology, 55(9), 656-658. https://doi.org/10.1136/jcp.55.9.656